文献速递白血病造血干细胞移植与细胞治疗

FLT3阳性急性髓系白血病中脐带血移植结局与同胞或无关供者移植相当:CIBMTR、EUROCORD和EBMT协作分析结果

Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
PubMed 文献 · Leukemia · 2017-01-25

该协作分析比较FLT3阳性急性髓系白血病完全缓解期接受脐带血、同胞或无关供者移植的结局。脐带血移植复发风险与同胞或无关供者移植相似,非复发死亡高于同胞但未高于无关供者,3年无白血病生存三组无显著差异,慢性移植物抗宿主病显著更低。

要点

  • 脐带血移植复发风险与同胞供者相似(HR 0.86,P=0.54),与无关供者相似(HR 0.81,P=0.43)。
  • 脐带血移植非复发死亡显著高于同胞供者(HR 2.32,P=0.02),与无关供者无显著差异(HR 1.72,P=0.07)。
  • 脐带血移植慢性移植物抗宿主病显著低于同胞(HR 0.59,P=0.03)和无关供者(HR 0.49,P=0.001)。

核心结论

  • 在缺乏HLA相合同胞供者时,脐带血是成人FLT3阳性急性髓系白血病的合适选择。
  • 脐带血即时可用性对早期复发常见的FLT3阳性急性髓系白血病可能尤为重要,使患者能在首次完全缓解(CR1)期接受移植。

研究设计与样本

  • CIBMTR、EUROCORD和EBMT协作分析,比较脐带血(n=126)、同胞供者(n=91)和无关供者(n=91)移植的结局。
  • 研究对象为完全缓解期接受异基因造血细胞移植的FLT3阳性急性髓系白血病患者。

主要发现

  • 复发风险:脐带血 vs 同胞供者 HR 0.86(P=0.54),无关供者 vs 同胞供者 HR 0.81(P=0.43)。
  • 非复发死亡:脐带血 vs 同胞供者 HR 2.32(P=0.02),脐带血 vs 无关供者 HR 1.72(P=0.07)。
  • 3年无白血病生存:脐带血39%(95%CI 30-47),同胞供者43%(95%CI 30-54),无关供者50%(95%CI 40-60),三组间无统计学显著差异。
  • 慢性移植物抗宿主病:脐带血 vs 同胞供者 HR 0.59(P=0.03),脐带血 vs 无关供者 HR 0.49(P=0.001)。
  • 无白血病生存的不良因素包括诊断时高白细胞计数和第二次完全缓解(CR2)期移植。

临床怎么用

  • 作者认为,在缺乏HLA相合同胞供者时,脐带血是成人FLT3阳性急性髓系白血病的合适选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FMS-like tyrosine kinase 3+ (FLT3+) acute myeloid leukemia (AML), which has poor prognosis because of high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126) (hazard ratio (HR) 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR 2.32, P=0.02), but not vs URD (HR 1.72, P=0.07). All three cohorts had statistically nonsignificant 3-year LFS: 39% (95% confidence interval (CI): 30-47) after UCB, 43% (95% CI: 30-54) after sibling and 50% (95% CI: 40-60) after URD. Chronic graft-versus-host disease rates were significantly lower after UCB compared with either sibling (HR 0.59, P=0.03) or URD (HR 0.49, P=0.001). Adverse factors for LFS included high leukocyte count at diagnosis and HCT during CR2 (second CR). UCB is a suitable option for adults with FLT3+ AML in the absence of an human leukocyte antigen-matched sibling and its immediate availability may be particularly important for FLT3+ AML where early relapse is common, thus allowing HCT in CR1 (first CR) when outcomes are best.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ustun C, Giannotti F, Zhang MJ, et al. Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis. Leukemia. 2017. PMID: 28119528. doi:10.1038/leu.2017.42

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。